Cover Image
市場調查報告書

Frontier Pharma:心血管疾病 - 各種First-in-Class分子標的,克服肺高血壓、心臟衰竭、動脈粥狀硬化性心血管疾病的未滿足需求

Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis

出版商 GBI Research 商品編碼 550298
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
Frontier Pharma:心血管疾病 - 各種First-in-Class分子標的,克服肺高血壓、心臟衰竭、動脈粥狀硬化性心血管疾病的未滿足需求 Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis
出版日期: 2017年08月01日 內容資訊: 英文 113 Pages
簡介

本報告提供心血管疾病調查分析,革新案例,概要,開發中產品的評估,計劃的評估,策略性整合等系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 革新案例

  • 生技藥品的機會擴大
  • 分子標的多樣化
  • 創新的First-in-Class產品 (劃時代的醫藥品)的開發現在也富有魅力
  • 法規、償付政策對First-in-Class產品的革新有利
  • 持續革新
  • 報告指南

第4章 臨床、商業形勢

  • 疾病概要
  • 徵兆,分期,預後
  • 診斷
  • 流行病學
  • 病因與病情生理
  • 管理和治療
  • 上市產品概要

第5章 開發中產品革新的評估

  • 概要
  • 開發平台:各開發階段,各分子類型
  • 開發平台:各分子標的
  • 市場與開發平台間的計劃比較分佈:各分子目標類別
  • 以新分子標的為目標的First-in-Class計劃

第6章 信號 (信號傳達) 網路與創新的調整

  • 信號傳達網路的複雜
  • 信號傳達途徑和First-in-Class分子標的整合
  • First-in-Class矩陣的評估

第7章 First-in-Class目標與開發平台計劃的評估

第8章 策略性整合

  • 產業整體First-in-Class交易
  • 授權交易
  • 共同開發交易
  • 事前參與/未參與的First-in-Class計劃

第9章 附錄

目錄
Product Code: GBIHC452MR

Executive Summary:

Cardiovascular disease (CVD) is a broad therapy area containing a range of indications relating to the human vasculature, heart and lipid levels. There is considerable first-in-class innovation within the CVD pipeline, comparable with the industry average. The molecular target groups with the highest proportion of first-in-class products include lipid metabolism, transmembrane and extracellular signaling, intracellular signal transduction and ion channels.

Of the four key CVD indications identified in this report (hypertension, heart failure, dyslipidemia and thrombosis), the hypertensive pipeline is the largest, with 238 products in development. The pipelines for heart failure and dyslipidemia are also large. Drugs in development for thrombosis, and specifically the treatment or prevention of thrombosis itself (as opposed to managing the underlying risk factors) has a relatively small pipeline of just 104 products. Overall, there are 1,400 plus products in the CVD pipeline.

There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market, first with the introduction of statins such as Lipitor (atorvastatin), and more recently with the introduction of PCSK9 inhibitors. Innovation continues within the dyslipidemia pipeline, The most promising first-in-class development within dyslipidemia focuses on targeting elements of the reverse lipid transport pathway. This is the process of high density lipoproteins (HDL) collecting cholesterol from cells, such as macrophages within atherosclerotic plaques, for removal from circulation in the liver via receptors such as scavenger receptor class B member 1 (SRB1).

Conventional classes of molecular target within the treatment of CVD are now showing relatively low levels of development, as innovation moves towards diverse targets related to the immune system, and transmembrane and extracellular signaling - with transmembrane proteins being a prominent source of innovation within the CVD pipeline.

This report has been designed to identify innovative pipeline programs across a therapy area with a focus on indications with high R&D activity and strong innovation, as well as a competitive commercial landscape and high levels of deal activity. Monitoring innovative new product developments is becoming an increasingly vital part of competitive intelligence for all market participants, and increasingly important for companies seeking strategic partnerships or looking to acquire technologies, products or other companies.

Scope:

  • With over 1,400 products in active development, the pipeline for CVD is extensive. Does current pipeline innovation hold the potential to change the CVD market in the near future?
  • There are 320 first-in-class products in the CVD market that act on a novel molecular target thatis not present in an approved product across any indication in the pharmaceutical industry. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
  • Analysis of the history of strategic consolidations revealed a modest level of deal activity in recent years, and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs that have not yet been involved in a licensing or co-development deal appear to be particularly promising?

Reasons to buy:

  • Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
  • Visualize the composition of the CVD market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze the CVD pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating CVD to overcome the unmet need in the market.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
  • Identify commercial opportunities in the CVD deals landscape by analyzing trends in licensing and co-development deals, and analyzing a curated list of CVD therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. Robust pipeline with attempts to meet unmet need
  • 2.2. Drugs targeting apolipoproteins and elements of the reverse lipid transport pathway offer potential new therapies for the treatment of dyslipidemia and atherosclerosis
  • 2.3. Cardiovascular disease pipeline emphasizes move away from conventional areas towards targets related to transmembrane and extracellular signaling

3. The Case for Innovation

  • 3.1. Growing Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Product Developments Remain Attractive
  • 3.4. Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
  • 3.5. Sustained Innovation in Cardiovascular Disease
  • 3.6. GBI Research Report Guidance

4. Clinical and Commercial Landscape

  • 4.1. Cardiovascular Disease Overview
  • 4.2. Symptoms, Disease Staging and Prognosis
    • 4.2.1. Symptoms
    • 4.2.2. Prognosis
  • 4.3. Diagnosis
    • 4.3.1. Blood Pressure Test
    • 4.3.2. Tests for Dyslipidemia
    • 4.3.3. Imaging Tests
    • 4.3.4. Stress Testing
  • 4.4. Epidemiology
  • 4.5. Etiology and Pathophysiology
    • 4.5.1. Etiology
    • 4.5.2. Pathophysiology
  • 4.6. Management and Treatment of Cardiovascular Disease
    • 4.6.1. Pharmacological Intervention
    • 4.6.2. Non-pharmacological Intervention
    • 4.6.3. Unmet Need
  • 4.7. Overview of Marketed Products

5. Assessment of Pipeline Product Innovation

  • 5.1. Overview
  • 5.2. Pipeline by Stage of Development and Molecule Type
    • 5.2.1. Cardiovascular Disease Overall
    • 5.2.2. Key Cardiovascular Indications
  • 5.3. Pipeline by Molecular Target
    • 5.3.1. Cardiovascular Disease
    • 5.3.2. Key Cardiovascular Indications
  • 5.4. Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class
  • 5.5. First-in-Class Programs Targeting Novel Molecular Targets
    • 5.5.1. Cardiovascular Disease

6. Signaling Network and Innovation Alignment within Cardiovascular Disease

  • 6.1. Complexity of Signaling Networks in Cardiovascular Disease
  • 6.2. Signaling Pathways and First-in-Class Molecular Target Integration
  • 6.3. First-in-Class Matrix Assessment

7. First-in-Class Target and Pipeline Program Evaluation

  • 7.1. Pipeline Programs Targeting Apelin Receptor
  • 7.2. Pipeline Programs Targeting Apolipoproteins (Apolipoprotein E, Apolipoprotein C-III and Apolipoprotein A-I)
    • 7.2.1. APOE
    • 7.2.2. APOCIII
    • 7.2.3. ApoA1
  • 7.3. Pipeline Programs Targeting Scavenger Receptor Class B Member 1(SRB1)
  • 7.4. Pipeline Programs Targeting Cholesteryl Ester Transfer Protein (CETP)
  • 7.5. Pipeline Programs Targeting Glutamyl Aminopeptidase
  • 7.6. Pipeline Programs Targeting E-selectin
  • 7.7. Pipeline Programs Targeting Platelet Glycoproteins (Platelet Glycoprotein VI and Platelet Glycoprotein Ib Alpha Chain)
    • 7.7.1. Platelet Glycoprotein VI (GP6)
    • 7.7.2. Platelet Glycoprotein Ib Alpha Chain (GP1ba)
  • 7.8. Pipeline Programs Targeting Tissue Factor
  • 7.9. Conclusion

8. Strategic Consolidations

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Licensing Deals
    • 8.2.1. Deals by Region, Value and Year
    • 8.2.2. Deals by Stage of Development and Value
    • 8.2.3. Deals by Molecule Type, Molecular Target and Value
    • 8.2.4. List of Deals with Disclosed Deal Values
  • 8.3. Co-development Deals
    • 8.3.1. Deals by Region, Value and Year
    • 8.3.2. Deals by Region, Year and Value
    • 8.3.3. Deals by Stage of Development and Value
    • 8.3.4. Deals by Molecule Type, Molecular Target and Value
    • 8.3.5. List of Deals with Disclosed Deal Values
  • 8.4. First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals

9. Appendix

  • 9.1. References
  • 9.2. Abbreviations
  • 9.3. Disease List
    • 9.3.1. Hypertension
    • 9.3.2. Dyslipidemia
    • 9.3.3. Heart failure
    • 9.3.4. Thrombosis
    • 9.3.5. CVD events
    • 9.3.6. Other
  • 9.4. Research Methodology
    • 9.4.1. Data integrity
    • 9.4.2. Innovative and meaningful analytical techniques and frameworks:
    • 9.4.3. Evidence based analysis and insight:
  • 9.5. Secondary Research
    • 9.5.1. Market Analysis
    • 9.5.2. Pipeline Analysis
    • 9.5.3. First-in-Class Matrix Assessment
    • 9.5.4. First-in-Class Target Profiles
    • 9.5.5. Licensing and Co-Development Deals
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Cardiovascular Disease Therapeutics Market, Systolic and Diastolic Blood Pressure Level and Corresponding Category
  • Table 2: Cardiovascular Disease Therapeutics Market, Total Cholesterol, LDL and HDL Levels and Corresponding Category
  • Table 3: Cardiovascular Disease Therapeutics Market, Global, Epidemiology of Cardiovascular Disease, Forecast 2017
  • Table 4: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Apelin Receptor, 2017
  • Table 5: Cardiovascular Therapeutics Market, Global, Pipeline Programs Targeting Apelin Receptor ,2017
  • Table 6: Cardiovascular Disease Therapeutics Market, Global, Key Features of Apolipoprotein E, 2017
  • Table 7: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Apolipoprotein E, 2017
  • Table 8: Cardiovascular Disease Therapeutics Market, Global, Key Features of Apolipoprotein-CIII, 2017
  • Table 9: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Apolipoprotein-CIII, 2017
  • Table 10: Cardiovascular Disease Therapeutics Market, Global, Key Features of Apolipoprotein-A1, 2017
  • Table 11: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Apolipoportein-A1, 2017
  • Table 12: Cardiovascular Disease Therapeutics Market, Global, Key Features of SRB1, 2017
  • Table 13: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting SRB1, 2017
  • Table 14: Cardiovascular Therapeutics Market, Global, Key Features of CETP, 2017
  • Table 15: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting CETP, 2017
  • Table 16: Cardiovascular Disease Therapeutics Market, Global, Key Features of Glutamyl Aminopeptidase, 2017
  • Table 17: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Glutamyl Aminopeptidase, 2017
  • Table 18: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of E-selectin, 2017
  • Table 19: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting E-selectin, 2017
  • Table 20: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Platelet Glycoprotein VI, 2017
  • Table 21: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Platelet Glycoprotein VI, 2017
  • Table 22: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Platelet Glycoprotein Ib Alpha Chain, 2017
  • Table 23: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Platelet Glycoprotein Ib Alpha Chain, 2017
  • Table 24: Cardiovascular Disease Therapeutics Market, Global, Key Features of Tissue Factor, 2017
  • Table 25: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Tissue Factor, 2017

List of Figures

  • Figure 1: Cardiovascular Disease and Associated Indications, Global, US, Innovation Trends in Product Approvals, 1987-2014
  • Figure 2: Cardiovascular Disease and Associated Indications, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
  • Figure 3: Cardiovascular Disease and Associated Indications, Global, Cardiovascular Disease Market by Molecular Target, 2017
  • Figure 4: Cardiovascular Disease and Associated Indications, Global, Pipeline by Therapy Area, 2017
  • Figure 5: Cardiovascular Disease, Global, Pipeline by Stage of Development and Molecule Type, 2017
  • Figure 6: Hypertension, Dyslipidemia, Thrombotic events, and Heart Failure, Global, Pipelines by Stage of Development, 2017
  • Figure 7: Hypertension, Dyslipidemia, Thrombotic Events, and Heart Failure, Global, Pipelines by Molecule Type, 2017
  • Figure 8: Cardiovascular Disease, Global, Pipeline by Molecular Target, 2017
  • Figure 9: Cardiovascular Disease, Global, Pipeline by Molecular Target Breakdown, 2017
  • Figure 10: Hypertension, Dyslipidemia, Thrombotic Events, Heart Failure, Global, Pipelines by Molecular Target, 2017
  • Figure 11: Cardiovascular Disease, Global, Pipeline and Marketed Products by Molecular Target Class, 2017
  • Figure 12: Cardiovascular Disease, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017
  • Figure 13: Cardiovascular Disease Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target (%), 2017
  • Figure 14: Cardiovascular Disease Therapeutics Market, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target, 2017
  • Figure 15: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 1
  • Figure 16: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 2
  • Figure 17: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 3
  • Figure 18: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 4
  • Figure 19: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 5
  • Figure 20: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 6
  • Figure 21: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 7
  • Figure 22: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 8
  • Figure 23: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 9
  • Figure 24: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 10
  • Figure 25: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 11
  • Figure 26: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 12
  • Figure 27: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 13
  • Figure 28: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 14
  • Figure 29: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 15
  • Figure 30: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Hypertension, 2017
  • Figure 31: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Heart Failure, 2017
  • Figure 32: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Dyslipidemia, 2017
  • Figure 33: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Thrombosis, 2017
  • Figure 34: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Other Atherosclerotic Cardiovascular Disease Indications, 2017
  • Figure 35: Cardiovascular Disease Therapeutics Market, Global, Industry-Wide Deals by Stage of Development and First-in-Class Status, 2006-2017
  • Figure 36: Cardiovascular Disease Therapeutics Market, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status, 2006-2017
  • Figure 37: Cardiovascular Disease Therapeutics, Global, Licensing Deals by Region, Value and Year, 2006-2017
  • Figure 38: Cardiovascular Disease Therapeutics, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2017
  • Figure 39: Cardiovascular Disease Therapeutics, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006-2017
  • Figure 40: Cardiovascular Disease Therapeutics, Global, Licensing Deals with Disclosed Deal Values, 2006-2017
  • Figure 41: Cardiovascular Disease Therapeutics, Global, Co-development Deals by Region, Value and Year, 2006-2017
  • Figure 42: Cardiovascular Disease Therapeutics, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
  • Figure 43: Cardiovascular Disease Therapeutics, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2017
  • Figure 44: Cardiovascular Disease Therapeutics, Global, Co-development Deals with Disclosed Deal Values, 2006-2017
  • Figure 45: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Co-development Deals, 2017 Part 1
  • Figure 46: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Co-development Deals, 2017 Part 2
  • Figure 47: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Co-development Deals, 2017 Part 3
Back to Top